Media Pack
News

Current Edition

Volume 16 Issue 1
 
Europe

Capricor Announces Initiation Of HOPE-2 Clinical Trial Of CAP-1002 For Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test the safety and ef...
2 May 2018 Europe | North America CAP-1002 | capricor
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte